ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1941

Interactions Between Genome-Wide Genetic Factors and Current Smoking in Determining SLE Risk

Jing Cui1, Soumya Raychaudhuri 2, Cameron Speyer 2, Susan Malspeis 2, Hongshu Guan 3, Xinyi Liu 2, Jessica Williams 2, Emma Davenport 4, Rachel Knevel 5, Elizabeth Karlson 2 and Karen Costenbader 2, 1Brigham Women's Hospital, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, 4Sanger Institute, Cambridge, United Kingdom, 5Leiden University Medical Center, Leiden, Netherlands

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: SLE, Weighted Genetic Risk Score and Smoking

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: Genetics, Genomics & Proteomics Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: We have previously reported that current smoking (or having recently quit within 4 years) was associated with elevated risk of SLE, in particular anti-dsDNA+ SLE. Genetic and environmental factors, such as smoking, may interact in determining SLE risk. We investigated whether interactions between smoking and genetic risk factors may influence SLE risk.

Methods: We identified subjects with validated SLE and DNA samples within the Nurses’ Health Studies (NHS) and Partners Healthcare Biobank (PHB). 673 SLE cases were matched to 3,276 controls without SLE on age, sex and race (matched on self-report race in NHS and by 1st 3 principle components of GWAS in PHB). All subjects had data on smoking prior to SLE diagnosis date or the matched index date in controls. DNA samples were genotyped and imputed using Haplotype Reference Consortium (Michigan) and SNP2HLA for HLA. SLE risk alleles were identified from published GWAS studies (mainly from White and Asian populations): https://www.ebi.ac.uk/gwas/. After pruning for linkage disequilibrium, 86 SNPs and 10 HLA alleles with genome wide significance p ≤ 5×10-8 were included in a new weighted genetic risk score (wGRS), weighted by log OR from published GWAS. The wGRS for all markers and for HLA alleles only were studied. Smoking was classified as current/quit within 4 years at SLE diagnosis vs. past/never smoker. wGRS was dichotomized as ≤ vs. > the median value in controls. We employed conditional logistic regression models for SLE or anti-double stranded DNA antibody + SLE (dsDNA+ SLE), conditioning on matching factors and controlling for cohort. We examined additive interactions using the attributable proportion (AP) due to interaction and tested for multiplicative interactions using a 1 d.f. χ2 test, for the wGRS as well as for individual risk alleles. We repeated analyses for risk of anti-dsDNA+ SLE. We examined interactions among all subjects and among Whites only.

Results: Characteristics of the cases and controls are shown in Table 1. High wGRS (OR 1.4, p 5.6×10-52) and current smoking (OR 1.5, p 0.0006) were individually both strongly associated with SLE risk. SLE risk was highest in those with high wGRS and current smoking, OR 5.58 (95% CI 4.1-7.6) (Table 2). A significant additive interaction between high vs. low wGRS and current/recent vs. past/never smoking was found (AP 0.37, p 1.5×10-4). Findings were similar for interactions associated with anti-dsDNA+ SLE risk. Significant multiplicative interactions between smoking and genotypes were found with specific genotypes, including HLA-DRB1-0102 (p 0.002) (Table 3), the weighted HLA GRS for SLE, but not with overall wGRS (p 0.18). Findings were similar when limited to Whites only. 

Conclusion: These findings support the hypothesis that smoking predisposes to SLE in the presence of genetic factors, with a greater than additive interaction with overall genetic risk and potentially greater than multiplicative interaction with certain genotypes. Studies should now investigate the mechanisms of these interactions and whether smoking influences the function of these genes in SLE pathogenesis.


Table 1


Table 2


Table 3


Disclosure: J. Cui, None; S. Raychaudhuri, None; C. Speyer, None; S. Malspeis, None; H. Guan, None; X. Liu, None; J. Williams, None; E. Davenport, None; R. Knevel, None; E. Karlson, None; K. Costenbader, Astra-Zeneca, 2, Glaxo Smith Kline, 2, Janssen Scientific Affairs, LLC, 2, Lupus Foundation of America, 2, Lupus Research Alliance, 2, Merck, 2.

To cite this abstract in AMA style:

Cui J, Raychaudhuri S, Speyer C, Malspeis S, Guan H, Liu X, Williams J, Davenport E, Knevel R, Karlson E, Costenbader K. Interactions Between Genome-Wide Genetic Factors and Current Smoking in Determining SLE Risk [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/interactions-between-genome-wide-genetic-factors-and-current-smoking-in-determining-sle-risk/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interactions-between-genome-wide-genetic-factors-and-current-smoking-in-determining-sle-risk/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology